Disease Overview：HER2-Positive Breast Cancer（HER2+ BC）
HER2-positive breast cancer is an aggressive subtype characterized by overexpression or amplification of the human epidermal growth factor receptor 2 (HER2) protein, detected via immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Accounting for approximately 15–20% of invasive breast cancers, it exhibits higher proliferation rates, increased risk of recurrence, and poorer prognosis without targeted intervention. However, the advent of HER2-directed therapies—such as trastuzumab, pertuzumab, ado-trastuzumab emtansine (T-DM1), and newer agents like fam-trastuzumab deruxtecan—has dramatically improved progression-free and overall survival. Current standard-of-care integrates neoadjuvant or adjuvant anti-HER2 regimens with chemotherapy, and increasingly, immunotherapy combinations and antibody-drug conjugates in advanced settings. Accurate molecular profiling, multidisciplinary tumor board review, and longitudinal monitoring are essential for optimal therapeutic sequencing.
China offers compelling advantages for international patients seeking HER2-positive breast cancer management. Leading oncology centers—including Fudan University Shanghai Cancer Center, Sun Yat-sen University Cancer Center, and Peking Union Medical College Hospital—house NCCN-aligned multidisciplinary teams with extensive experience in complex HER2+ cases, including residual disease post-neoadjuvant therapy and metastatic refractory disease. These institutions utilize state-of-the-art platforms such as next-generation sequencing (NGS), digital pathology, and PET-MRI for precision staging and response assessment. Clinical trial participation rates exceed global averages, granting early access to novel biologics and ADCs. Five-year survival rates for stage II–III HER2+ disease align closely with U.S. and EU benchmarks, supported by robust real-world evidence from national registries. Crucially, treatment costs—including diagnostics, targeted biologics, and supportive care—are typically 40–60% lower than in the U.S., UK, or Singapore, without compromising clinical rigor or regulatory compliance (CFDA/NMPA-approved agents only).
As a dedicated medical tourism agency, we facilitate seamless cross-border care: verifying hospital credentials, coordinating appointments with certified oncologists, providing itemized, transparent pricing in advance, arranging visa support, accommodation, interpreter services, and post-treatment follow-up coordination—all tailored to individual clinical and logistical needs.
HER2-Positive Breast Cancer: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: HER2-Positive Breast Cancer
Non-Surgical/Medical Therapies
*Eligibility*: Confirmed HER2-positive status (IHC 3+ or FISH-amplified), no contraindications to targeted therapy.
- •Neoadjuvant/Adjuvant Dual HER2 Blockade (Trastuzumab + Pertuzumab)
- Trastuzumab (440 mg IV): $580–$620 - Pertuzumab (420 mg IV): $1,150–$1,280 - *Supportive care & monitoring*: - Cardiac echo (baseline + q3mo): $45–$65 - LVEF monitoring (BNP + ECG): $25–$35 - Monthly CBC/LFTs: $18–$22
- •Adjuvant Trastuzumab Monotherapy (1 year)
- *Infusion & nursing fees (per cycle)*: $110–$140
- •T-DM1 (Ado-trastuzumab emtansine) for residual disease post-neoadjuvant
- *Pre-infusion labs (CBC, LFTs, bilirubin)*: $32–$40
Surgical/Procedural Interventions
*Eligibility*: Clinically resectable tumor (cT1–4, N0–2, M0); adequate cardiac/respiratory reserve.
- •Lumpectomy + Sentinel Lymph Node Biopsy (SLNB)
- *Pre-op workup (mammogram + ultrasound + core biopsy)*: $380–$460 - *Pathology (HER2/FISH retesting, SLN analysis)*: $290–$340
- •Mastectomy ± Immediate Implant Reconstruction
- *Implant reconstruction (silicone)*: $5,200–$6,300 - *Pre-op MRI (if indicated for multifocality)*: $420–$490
- •Axillary Lymph Node Dissection (ALND)
Special/Complex Scenarios
- •Metastatic Disease (CNS involvement):
- *Brain MRI (with contrast)*: $310–$370
- •Cardiac toxicity requiring LVEF recovery:
Quick Selection Guide
- •Early-stage, <65 y, no comorbidities: Lumpectomy + dual HER2 blockade — optimal balance of efficacy, organ preservation, and cost (~$14,200–$16,800 total)
- •Locally advanced, budget-constrained: Mastectomy + trastuzumab monotherapy — avoids high-cost pertuzumab/T-DM1 (~$13,500–$15,100)
- •Elderly (>75 y) or severe cardiac disease: Trastuzumab monotherapy + radiotherapy (if lumpectomy deferred) — minimizes procedural risk (~$10,200–$11,800)
- •Residual disease post-neoadjuvant: T-DM1 — standard-of-care despite higher upfront cost (~$34,000–$37,500)
- •Metastatic with brain mets: Tucatinib-based regimen — only FDA/NMPA-approved CNS-penetrant option (~$20,000–$22,500 initial phase)
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended HER2-Positive Breast Cancer Medical Vacation Packages
Curated transparent all-inclusive packages combining HER2-Positive Breast Cancer treatment with China top medical destinations:
